{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T17:23:33Z","timestamp":1785605013252,"version":"3.56.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study describes the characteristics, survival and prognostic factors in a cohort of patients with bone metastases (BM) from differentiated thyroid carcinoma (DTC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a multicenter retrospective observational study conducted in Spain, including patients diagnosed with DTC and BM between 1980 and 2022.\u00a0A Cox regression analysis was performed to examine prognostic factors for survival. Kaplan-Meier and log-rank tests were performed for survival analysis and comparison between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 133 patients were included with a median follow-up of 40 (17-70) months. Seventy patients (52.6%) had BM at the initial diagnosis. Fifty-two (39.1%) had follicular carcinoma. Sixty-six (49.6%) presented multiple BM. The most frequent location was the spine (63.2%). Other metastases were present at diagnosis in 88 (66.2%), mainly lung (60.9%). BM were treated with I131 in 91 (68.4%) patients, with BM uptake in 63 (47.4%). Fifty-six (42.1%) received treatment with multikinase inhibitors. Fifty-three (3.9%) had skeletal-related events. Seventy-two (54.1%) died. The 3-, 5- and 10-year survival was 53.5, 39.5% and 28.5%, respectively. Significant prognostic factors in the multivariate analysis were the presence of lymph node metastases (N1) HR 1.71 (95% CI 1.005-2.098; p=0.048), BM treatment with I131 HR 0.532 (95% CI 0.304-0.931; p=0.027) and age \u226567 years at BM diagnosis HR 1.991 (95% CI 1.142-3.47; p=0.015).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Survival of DTC patients with BM treated in a Spanish cohort was 39.5% at 5 years and 28.5% at 10 years. Patients with BM treated with I131 appear to have a better outcome in terms of mortality and the presence of lymph node involvement and age over 67 years were associated with higher mortality.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1466245","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T04:43:17Z","timestamp":1730954597000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors"],"prefix":"10.3389","volume":"15","author":[{"given":"Suset","family":"Due\u00f1as-Disotuar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pi\u00f1ar-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"de Lara-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sastre-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Anda-Api\u00f1\u00e1niz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Oleaga-Alday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JC","family":"Galofr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Orois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Alc\u00e1zar-L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Mart\u00ednez-Guasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"S\u00e1nchez-Ragnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"G\u00e1lvez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Familiar-Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Mart\u00edn-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana R.","family":"Romero-Lluch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.4983","article-title":"Use of multikinase inhibitors\/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine-resistant differentiated thyroid cancer","volume":"11","author":"Navarro-Gonzalez","year":"2022","journal-title":"Cancer Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100282","DOI":"10.1016\/j.jbo.2020.100282","article-title":"Bone metastases in thyroid cancer","volume":"21","author":"I\u00f1iguez-Ariza","year":"2020","journal-title":"J Bone Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0582","article-title":"Improved survival after multimodal approach with 131I treatment in patients with bone metastases secondary to differentiated thyroid cancer","volume":"29","author":"Wu","year":"2019","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"B4","article-title":"Osseous metastases in thyroid cancer: unveiling risk factors, disease outcomes, and treatment impact","volume":"15","author":"Za","year":"2023","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-23-0086","article-title":"Bone metastases from differentiated thyroid cancer: characteristics and prognostic factors in a multicenter series","volume":"12","author":"Pi\u00f1ar-Guti\u00e9rrez","year":"2023","journal-title":"Eur Thyroid J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3906","article-title":"Skeletal complications and mortality in thyroid cancer: A population-based study","volume":"102","author":"Choksi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","first-page":"598","article-title":"Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma","volume":"37","author":"Schlumberger","year":"1996","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0093","article-title":"Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer","volume":"96","author":"Qiu","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.5858\/2000-124-1440-BMFTC","article-title":"Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates","volume":"124","author":"Tickoo","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12020-017-1455-6","article-title":"Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience","volume":"59","author":"Mazziotti","year":"2018","journal-title":"Endocrine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2005.03.011","article-title":"Management of bone metastases in cancer: a review","volume":"56","author":"Selvaggi","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2009.10.009","article-title":"Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma","volume":"147","author":"Orita","year":"2010","journal-title":"Surgery"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000502229","article-title":"2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur Thyroid J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in\u00a0radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet Lond Engl"},{"key":"B16","volume-title":"TNM Classification of Malignant Tumours","year":"2022"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-023-01826-z","article-title":"Prognosis of thyroid carcinoma patients with osseous metastases: an SEER-based study with machine learning","volume":"37","author":"Shi","year":"2023","journal-title":"Ann Nucl Med"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294343","article-title":"A long-term retrospective cohort-based risk-benefit analysis of augmenting total cumulative I-131 activity to 37GBq in differentiated thyroid cancer patients with skeletal metastases","volume":"18","author":"Kanankulam Velliangiri","year":"2023","journal-title":"PloS One"},{"key":"B19","article-title":"Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma","volume":"106","author":"Marcocci","year":"1989","journal-title":"Surgery"},{"key":"B20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000494719","article-title":"Bone metastases from thyroid carcinoma of follicular origin: A single institutional experience","volume":"8","author":"Matta-Coelho","year":"2019","journal-title":"Eur Thyroid J"},{"key":"B21","article-title":"Survival time and \u201ccure\u201d in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy","volume":"23","author":"Beierwaltes","year":"1982","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-63-4-960","article-title":"Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma","volume":"63","author":"Schlumberger","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s002590000420","article-title":"Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age","volume":"28","author":"Petrich","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-67-3-501","article-title":"Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables","volume":"67","author":"Ruegemer","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-010-9398-4","article-title":"Relationship between visceral adiposity and bone mineral density in Korean adults","volume":"87","author":"Choi","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2018-0465","article-title":"LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES","volume":"25","author":"Slook","year":"2019","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4497-0","article-title":"Prospective evaluation of Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma","volume":"22","author":"Orita","year":"2015","journal-title":"Ann Surg Oncol"}],"updated-by":[{"DOI":"10.3389\/fendo.2024.1542771","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1466245\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T08:35:05Z","timestamp":1736325305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1466245\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":27,"alternative-id":["10.3389\/fendo.2024.1466245"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1466245","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fendo.2024.1542771","asserted-by":"object"}]},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"article-number":"1466245"}}